Previous Close | 4.8100 |
Open | 4.7900 |
Bid | 4.4700 x 100 |
Ask | 4.5100 x 100 |
Day's Range | 4.4650 - 4.8600 |
52 Week Range | 4.2500 - 12.2900 |
Volume | |
Avg. Volume | 205,884 |
Market Cap | 173.422M |
Beta (5Y Monthly) | 0.09 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.4200 |
Earnings Date | May 14, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.50 |
Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...